OBJECTIVE: To compare the use of meal replacements or medication during weight maintenance subsequent to weight loss using a very low-energy diet (VLED) in overweight or obese adults. DESIGN: Participants followed a liquid VLED of 2177 kJ for 12 weeks followed by 4 weeks of re-orientation to solid foods. Participants were randomized at week 16 to receive either meal replacements or Orlistat both combined with a structured meal plan containing an energy value calculated to maintain weight loss. SUBJECTS:Sixty-four women (age = 49.9 +/- 10 y, weight = 101.6 +/- 17.1 kg, height = 164.9 +/- 6.0 cm, BMI = 36.7 +/- 5.4 kg/m(2)) and 28 men (age = 53.7 +/- 9.6 y, weight = 121.8 +/- 16.0 kg, height = 178.7 +/- 5.6 cm, BMI = 37.8 +/- 4.9 kg/m(2)) completed a 1 year weight management program. Behavioral weight management clinics included topics on lifestyle, physical activity (PA), and nutrition. Participants met for 90 min weekly for 26 weeks, and then biweekly for the remaining 26 weeks. OUTCOMES: Minutes of PA, fruits and vegetables (FV), and pedometer steps were recorded on a daily basis and reported at each group meeting. Body weight was obtained at each group meeting. RESULTS: During VLED, the MR group decreased body weight by 22.8 +/- 6.1 kg and the Orlistat group decreased body weight by 22.3 +/- 6.1 kg. During weight maintenance, there was no significant group by time interaction for body weight, PA, FV consumption, or pedometer steps. At week 16, the meal replacement group had a body weight of 85.4 +/- 14.3 kg that increased to 88.1 +/- 16.5 kg at 52 weeks (p < 0.05). At week 16, the Orlistat group had a body weight of 85.7 +/- 17.9 kg that increased to 88.5 +/- 20.3 kg at 52 weeks (p < 0.05). CONCLUSIONS: Subsequent to weight loss from a VLED, meal replacements and Orlistat treatments were both effective in maintaining weight significantly below baseline levels over a 52 week period of time. Meal replacements may be a viable alternative strategy to medications for weight maintenance.
RCT Entities:
OBJECTIVE: To compare the use of meal replacements or medication during weight maintenance subsequent to weight loss using a very low-energy diet (VLED) in overweight or obese adults. DESIGN:Participants followed a liquid VLED of 2177 kJ for 12 weeks followed by 4 weeks of re-orientation to solid foods. Participants were randomized at week 16 to receive either meal replacements or Orlistat both combined with a structured meal plan containing an energy value calculated to maintain weight loss. SUBJECTS: Sixty-four women (age = 49.9 +/- 10 y, weight = 101.6 +/- 17.1 kg, height = 164.9 +/- 6.0 cm, BMI = 36.7 +/- 5.4 kg/m(2)) and 28 men (age = 53.7 +/- 9.6 y, weight = 121.8 +/- 16.0 kg, height = 178.7 +/- 5.6 cm, BMI = 37.8 +/- 4.9 kg/m(2)) completed a 1 year weight management program. Behavioral weight management clinics included topics on lifestyle, physical activity (PA), and nutrition. Participants met for 90 min weekly for 26 weeks, and then biweekly for the remaining 26 weeks. OUTCOMES: Minutes of PA, fruits and vegetables (FV), and pedometer steps were recorded on a daily basis and reported at each group meeting. Body weight was obtained at each group meeting. RESULTS: During VLED, the MR group decreased body weight by 22.8 +/- 6.1 kg and the Orlistat group decreased body weight by 22.3 +/- 6.1 kg. During weight maintenance, there was no significant group by time interaction for body weight, PA, FV consumption, or pedometer steps. At week 16, the meal replacement group had a body weight of 85.4 +/- 14.3 kg that increased to 88.1 +/- 16.5 kg at 52 weeks (p < 0.05). At week 16, the Orlistat group had a body weight of 85.7 +/- 17.9 kg that increased to 88.5 +/- 20.3 kg at 52 weeks (p < 0.05). CONCLUSIONS: Subsequent to weight loss from a VLED, meal replacements and Orlistat treatments were both effective in maintaining weight significantly below baseline levels over a 52 week period of time. Meal replacements may be a viable alternative strategy to medications for weight maintenance.
Authors: Amanda N Szabo; Richard A Washburn; Debra K Sullivan; Jeffery J Honas; Matthew S Mayo; Jeannine Goetz; Jaehoon Lee; Joseph E Donnelly Journal: Contemp Clin Trials Date: 2013-09-04 Impact factor: 2.226
Authors: Christie A Befort; Jennifer R Klemp; Heather L Austin; Michael G Perri; Kathryn H Schmitz; Debra K Sullivan; Carol J Fabian Journal: Breast Cancer Res Treat Date: 2011-12-25 Impact factor: 4.872
Authors: Amanda N Szabo-Reed; Florence J Breslin; Anthony M Lynch; Trisha M Patrician; Laura E Martin; Rebecca J Lepping; Joshua N Powell; Hung-Wen Henry Yeh; Christie A Befort; Debra Sullivan; Cheryl Gibson; Richard Washburn; Joseph E Donnelly; Cary R Savage Journal: Contemp Clin Trials Date: 2014-12-19 Impact factor: 2.226
Authors: James D LeCheminant; Bryan K Smith; Eric C Westman; Mary C Vernon; Joseph E Donnelly Journal: Lipids Health Dis Date: 2010-06-01 Impact factor: 3.876
Authors: Anna M Gorczyca; Richard A Washburn; Lauren Ptomey; Matthew S Mayo; Debra K Sullivan; Cheryl A Gibson; Robert Lee; Sarah Stolte; Joseph E Donnelly Journal: Contemp Clin Trials Date: 2018-02-15 Impact factor: 2.226